An update on autoantibodies in sclerodermaMecoli, Christopher A.; Casciola-Rosen, LiviaCurrent Opinion in Rheumatology: November 2018 - Volume 30 - Issue 6 - p 548–553 doi: 10.1097/BOR.0000000000000550 RAYNAUD PHENOMENON, SCLERODERMA, OVERLAP SYNDROMES AND OTHER FIBROSING SYNDROMES: Edited by John Varga Buy Abstract Author InformationAuthors Article MetricsMetrics Purpose of review New research continues to provide important insights into the utility of antibody specificities. This review provides an update of recent findings, and the important insights they provide into disease mechanism. Recent findings A growing number of autoantibodies have been discovered in scleroderma patients with unique clinical associations. A subgroup of these antibodies may have functional consequences and contribute to disease pathogenesis, driving the vascular and fibrotic phenotype. Recent research into the relationship between malignancy and scleroderma onset provides important new insights into disease mechanism, and highlights the utility of autoantibodies as unique research probes. Summary Continued advances in the study of scleroderma antibody specificities has led to important insights into disease pathogenesis and clinical subgrouping. These advances include newly described specificities, functional antibodies and an emerging understanding of the cancer–scleroderma relationship. Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA Correspondence to Livia Casciola-Rosen, PhD, Division of Rheumatology, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, MFL Bldg, Center Tower, Suite 4100, Baltimore, MD 21224, USA. E-mail: email@example.com Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.